Steinhauer H B, Wilms H, Schollmeyer P
Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:1032-6.
In a prospective study the diagnostic value of urinary thromboxane B2 (TXB2) and beta 2-microglobulin (beta MG) in renal allograft rejection was studied in 34 patients after transplantation. Twenty-four episodes of rejection were diagnosed by clinical symptoms. The clinical diagnosis of rejection was confirmed by an increase of urinary TXB2 in 21 (88%) cases. The augmented renal excretion of TXB2 proceded the clinical signs of rejection for 2.0 +/- 0.75 days. The symptoms in the remaining three (12%) cases of supposed allograft rejection without increased urinary TXB2 were caused by non-immunological events (urinary tract infection, acute tubular necrosis). No elevated TXB2 excretion was observed during urinary tract infection, sepsis, and acute tubular necrosis whereas urinary beta MG increased during these events as during transplant rejection. Urinary TXB2 was found to be an early, specific, and sensitive marker of renal allograft rejection with greater reliability than beta MG excretion or clinical signs of rejection.
在一项前瞻性研究中，对34例肾移植患者移植后尿血栓素B2（TXB2）和β2-微球蛋白（βMG）在肾移植排斥反应中的诊断价值进行了研究。通过临床症状诊断出24次排斥反应发作。21例（88%）患者经尿TXB2升高证实为临床诊断的排斥反应。TXB2的肾脏排泄增加先于排斥反应的临床体征2.0±0.75天出现。其余3例（12%）疑似同种异体移植排斥反应但尿TXB2未升高的病例，其症状由非免疫性事件（尿路感染、急性肾小管坏死）引起。在尿路感染、败血症和急性肾小管坏死期间未观察到TXB2排泄升高，而在此类事件期间尿βMG如同在移植排斥反应期间一样升高。发现尿TXB2是肾移植排斥反应的早期、特异性和敏感标志物，比βMG排泄或排斥反应的临床体征更具可靠性。
